Ponazuril (INN), sold by Merial, Inc.,[1] now part of Boehringer Ingelheim,[2] under the trade name Marquis (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.

[3][4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite.

[citation needed] Along with its analogue ACD856, ponazuril (also known as ACD855) is a positive allosteric modulator of the tropomyosin receptor kinases TrkA and TrkB.

This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.This veterinary medicine–related article is a stub.